Athol U Wells

Dec 31, 2024 | respiratory-research.biomedcentral.com | Athol U Wells |Ayodeji Adegunsoye |Vincent Cottin |Sonye Danoff |Anand Devaraj |Kevin Flaherty | +7 more

Surveys were completed between March 2022 and July 2023. The international guideline on the definition of PPF [1] was published between distribution of the first and second rounds of the survey. The first survey was sent to 405 physicians in 32 countries and completed by 207, of whom 131 completed the second round and 94 completed the third round. The clinical experience of the respondents is summarised in Table S1 in Additional file 1.

Jun 27, 2024 | bmjopenrespres.bmj.com | Kevin Flaherty |Kevin Brown |Athol U Wells |Emmanuelle Clerisme-Beaty

The PF-ILD trial (1199.247, NCT02999178) is a multicentre, prospective, randomised, double-blind, placebo-controlled study to investigate the efficacy and safety of nintedanib in patients with progressive fibrosing lung disease over 52 weeks. The study is conducted at specialised referral centres experienced in ILD management in approximately 15 countries of the Americas, Europe and Asia.